190 related articles for article (PubMed ID: 37967750)
1. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting.
Gupta U; Ruli T; Buttar D; Shoreibah M; Gray M
Am J Med Sci; 2024 Feb; 367(2):77-88. PubMed ID: 37967750
[TBL] [Abstract][Full Text] [Related]
2. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
Kanwal F; Neuschwander-Tetri BA; Loomba R; Rinella ME
Hepatology; 2024 May; 79(5):1212-1219. PubMed ID: 38445559
[TBL] [Abstract][Full Text] [Related]
4. NIS2+
Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
[TBL] [Abstract][Full Text] [Related]
5. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
[TBL] [Abstract][Full Text] [Related]
6. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J; Fan JG; Francque SM
United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
Srivastava A; Gailer R; Tanwar S; Trembling P; Parkes J; Rodger A; Suri D; Thorburn D; Sennett K; Morgan S; Tsochatzis EA; Rosenberg W
J Hepatol; 2019 Aug; 71(2):371-378. PubMed ID: 30965069
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
11. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
12. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
13. CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.
Virović Jukić L; Grgurević I; Mikolašević I; Filipec Kanižaj T; Milić S; Mrzljak A; Premužić M; Hrstić I; Knežević-Štromar I; Ljubičić N; Ostojić R; Stojsavljević Shapeski S; Amerl-Šakić V; Marković NB; Rađa M; Soldo D; Sobočan N; Lalovac M; Puljiz Ž; Podrug K; Ladić D
Acta Clin Croat; 2021 Dec; 60(Suppl 2):36-52. PubMed ID: 35528151
[TBL] [Abstract][Full Text] [Related]
14. Natural history of metabolic dysfunction-associated steatotic liver disease.
Lekakis V; Papatheodoridis GV
Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
[TBL] [Abstract][Full Text] [Related]
15. Identifying High-Risk Patients With Nonalcoholic Fatty Liver Disease: An Opportunity for Intervention Within the Primary Care Setting.
No JS; Buckholz A; Han C; Matthews S; Fortune B; Krisko T; Newberry C; Kumar S
J Clin Gastroenterol; 2023 Oct; 57(9):956-961. PubMed ID: 36731002
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Muddle. MASLD and MASH on the Horizon.
Meagher T
J Insur Med; 2023 Jul; 50(2):147-149. PubMed ID: 38358924
[TBL] [Abstract][Full Text] [Related]
17. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
[TBL] [Abstract][Full Text] [Related]
18. Management of NAFLD in primary care settings.
Wong VWS; Zelber-Sagi S; Cusi K; Carrieri P; Wright E; Crespo J; Lazarus JV
Liver Int; 2022 Nov; 42(11):2377-2389. PubMed ID: 35986897
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
20. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
